Accessibility Menu
Inhibitor Therapeutics logo

Inhibitor Therapeutics(OTC) INTI

Market Cap$12.87MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (1997)-99%
5 Year-59%
1 Year+68%
1 Month-7%
$0.07
-16.85%
-0.02Today
Inhibitor Therapeutics last closing stock price
MetricPriceDate
Last closeUSD 0.072026-09-03
Inhibitor Therapeutics stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-16.8%USD 0.092026-08-27
1 month-7.44%USD 0.082026-08-04
3 month-3.83%USD 0.082026-06-05
Year to date+64.56%USD 0.052025-12-31
1 year+67.61%USD 0.042025-08-29
3 year+68.3%USD 0.042023-08-30
5 year-58.86%USD 0.182021-09-03
Since inception-99.17%USD 8.881997-10-29

Inhibitor Therapeutics Financials at a Glance

Market Cap

$12.87MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

-$3.31M

EPS (TTM)

-$0.02

P/E Ratio

-3.86

Dividend

$0.00

Beta (Volatility)

-0.20 (Low)

Price

$0.07

Volume

1,200

Open

$0.06

Previous Close

$0.07

Daily Range

$0.06 - $0.07

52-Week Range

$0.04 - $0.12

Estimated Earnings Date

Aug 14, 2026

INTI News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Inhibitor Therapeutics

Inhibitor Therapeutics develops medicines for rare cancers and growth disorders. Its main drug aims to help people with chronic skin cancer. The company focuses on improving existing drugs for new uses.

What’s in the Medicine Cabinet?

  • SUBA-Itraconazole: Oral drug for rare skin cancer (basal cell carcinoma nevus syndrome); 0% of revenue as company is pre-revenue.
  • Prostate Cancer Program: Early-stage research using SUBA-Itraconazole for prostate cancer; 0% of revenue.
  • Lung Cancer Program: Early-stage research for lung cancer treatment; 0% of revenue.
  • Micro-ITRA Formulation: Proprietary version of itraconazole to improve absorption; 0% of revenue.

Growth Spurts and Strategic Moves

  • 2023: Signed exclusive patent license with Johns Hopkins University for new drug uses.
  • 2025: Entered partnership with Avior Bio to develop improved drug formulations.
  • 2025: Signed consulting agreement with Frameshift Management for regulatory strategy.
  • 2026: Requested FDA meeting for main drug program; responses expected May 2026.

Why This Company Isn’t Like the Others

Inhibitor Therapeutics repurposes existing drugs, aiming for faster development and lower risk. Its focus on rare diseases targets small but defined patient groups. The company holds exclusive rights to key patents and relies on partnerships for drug formulation.

Five Things You Need to Know

  • Revenue was $0 in 2025, unchanged from 2024 and 2023.
  • Net loss was $3.3 million in 2025, flat from 2024.
  • Cash and equivalents fell to $2.4 million at end-2025, down 57.6% from 2024.
  • Operating cash flow was negative $761,245 in QQ3 2025, down 5.7% year-over-year.
  • Company has no commercial products or sales channels as of 2025.

Bottom Line

Inhibitor Therapeutics remains a pre-revenue biotech focused on rare cancer treatments. Its future depends on clinical progress and securing new funding.

AI Generated • Apr 16, 2026

Industry

Biotechnology

Sector

Health Care

Employees

8

CEO

Frank E. O'Donnell, Jr.

Website

www.inhibitortx.com

Headquarters

Tampa, FL 33629-7264, US

INTI Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

227.11%

Return on Capital

N/A

Return on Assets

-519.14%

Earnings Yield

-25.91%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$12.87MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

173.79M

Volume

1.20K

Avg. Volume

7.75K

Financials (TTM)

Gross Profit

$0.00

Operating Income

-$3.37M

EBITDA

-$3.34M

Operating Cash Flow

-$3.22M

Capital Expenditure

$0.00

Free Cash Flow

-$3.22M

Cash & ST Invst.

$515.76K

Total Debt

$47.83K

Inhibitor Therapeutics Performance Analysis

Inhibitor Therapeutics annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 0N/A
20232023-12-31USD 0N/A
20242024-12-31USD 0N/A
20252025-12-31USD 0N/A
Inhibitor Therapeutics sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30N/A
Q42025-12-31N/A
Q12026-03-31N/A
Q22026-06-30N/A
Inhibitor Therapeutics annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD 0.03N/A
20232023-12-31USD -0.02N/A
20242024-12-31USD -0.0210.2%
20252025-12-31USD -0.02-1.5%
Inhibitor Therapeutics sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30-7.9%
Q42025-12-31-82.9%
Q12026-03-3146.7%
Q22026-06-3012.5%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

$0.00

N/A

Gross Margin

0.00%

N/A

Market Cap

$12.87MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$1.61M

N/A

Employees

8

N/A

Net Income

-$613.93K

+7.0%

EBITDA

-$618.60K

+11.1%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

$515.76K

-86.2%

Total Debt

$47.83K

-38.7%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$21.57K

-58.6%

Short Term Debt

$26.26K

+1.1%

Return on Assets

-5.19%

N/A

Return on Invested Capital

-7.29%

N/A

Free Cash Flow

-$775.22K

-32.7%

Operating Cash Flow

-$775.22K

-32.7%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
DVHGFDevonian Health Group Inc.
$7.00+0.00%
CUBTCurative Biotechnology, Inc.
$0.75-16.67%
LIANYLianBio
$0.04-2.50%
PHRRFPharmaTher Holdings Ltd.
$0.04+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$9.15-0.12%
NVDANvidia
$230.36+0.01%
PATHUiPath
$15.19-0.17%
INTCIntel
$95.80+0.05%

Questions About INTI

What is the current price of Inhibitor Therapeutics?

Inhibitor Therapeutics is trading at $0.07 per share.

What is the 52-week range for Inhibitor Therapeutics?

Over the past 52 weeks, Inhibitor Therapeutics has traded between $0.04 and $0.12.

How much debt does Inhibitor Therapeutics have?

As of the most recent reporting period, Inhibitor Therapeutics reported total debt of $47.83K.

How much cash does Inhibitor Therapeutics have on hand?

Inhibitor Therapeutics reported $515.76K in cash and cash equivalents in its most recent financial results.

What is Inhibitor Therapeutics’s dividend yield?

Inhibitor Therapeutics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services